Efficacy and safety of Herceptin® in women with metastatic breast cancer: Results from pivotal clinical studies

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 4, 2001, Pages

  Smith, I E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Clinical efficacy; HER2; Herceptin ; Safety

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT;

EID: 0035712194     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200112004-00002     Document Type: Conference Paper

References (34)

1. Cancer of the breast
2. Recent trends in US breast cancer incidence, survival, and mortality rates
3. Treatment of metastatic disease
4. Growth factors and cancer
5. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
6. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
7. The neu oncogene encodes an epidermal growth factor receptor-related protein
8. The subcellular localization of the neu protein in human normal and neoplastic cells
9. The biology of erbB-2/neu/HER-2 and its role in cancer
10. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
11. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
12. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
13. Prognostic importance of c-erbB-2 expression in breast cancer
14. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
15. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
16. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
17. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
18. Addition of Herceptin® (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational, controlled phase III trial
19. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer: A phase III, multinational, randomized, controlled trial
20. Pharmacologic insights into the future of Herceptin®
21. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
22. Health-related quality of life (HRQL) of patients with HER-2 overexpressing, metastatic breast cancer (MBC) treated with Herceptin (trastuzumab) as a single agent
23. Overall survival (OS) advantage to Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
24. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin)
25. Health-related quality of life (HRQL) in women with HER2-overexpressing metastatic breast cancer (MBC) in a phase III study of Herceptin (R) plus chemotherapy versus chemotherapy alone
26. Anti-HER2 therapy: How to use Herceptin® in clinical practice
27. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993
28. Tolerability in patients receiving Herceptin® with or without chemotherapy
29. Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer
30. First-line, non-hormonal, treatment of woman with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
31. The discovery and validation of new drug targets in cancer
32. Receptor blockade with monoclonal antibodies as anti-cancer therapy
33. Rituximab immunotherapy for non-Hodgkin's lymphoma